Summary
Administering rectal artesunate suppositories to patients with severe malaria before they receive parenteral and oral consolidation therapy was found to reduce mortality more than a decade ago. The roll-out of rectal artesunate could combat the current global increase in malaria deaths. Instead, on Jan 27, 2022, WHO recommended a moratorium on the deployment of rectal artesunate and in doing so stopped the roll-out of a lifesaving intervention. This decision was based mainly on the results from an observational study that is part of a larger project being conducted in Nigeria, Uganda, and DR Congo. The Community Access to Rectal Artesunate for Malaria (CARAMAL) project was not set up to provide patient transport to referral health-care centres for parenteral artesunate administration or logistic support to assure the availability of parenteral and oral antimalarial consolidation therapy. Using a before-after study design, which is known to be prone to bias, the study found that case fatality rates of severe malaria increased instead of decreased after the roll-out of rectal artesunate. However, the study and its analysis have methodological flaws that provide an alternative explanation for study findings. Instead of further delaying the roll-out of rectal artesunate, there is an urgent need for a concerted effort to provide rectal artesunate as originally intended, where and when it is needed.
This article is available free of charge.
Simply log in to access the full article, or register for free if you do not yet have a username and password.
Already registered?
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Not yet registered?
Register for free
References
- 1.
World malaria report 2021.https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021Date: Dec 6, 2021Date accessed: November 30, 2022
- 2.
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.Lancet. 2005; 366: 717-725
- 3.
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.Lancet. 2010; 376: 1647-1657
- 4.
Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study.Lancet. 2004; 363: 1598-1605
- 5.
Pharmacokinetic study of rectal artesunate in children with severe malaria in Africa.Antimicrob Agents Chemother. 2021; 65: e02223-e02224
- 6.
Pre-referral rectal artesunate for severe malaria.Cochrane Database Syst Rev. 2014; 5CD009964
- 7.
Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea.Antimicrob Agents Chemother. 2006; 50: 968-974
- 8.
Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria.Antimicrob Agents Chemother. 2001; 45: 509-516
- 9.
Efficacy and tolerability of a sequential, artesunate suppository plus mefloquine, treatment of severe falciparum malaria.Ann Trop Med Parasitol. 1995; 89: 469-475
- 10.
Saving lives, buying time: economics of malaria drugs in an age of resistance.The National Academies Press, Washington, DC2004
- 11.
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial.Lancet. 2009; 373: 557-566
- 12.
Pre-referral rectal artesunate in severe malaria: flawed trial.Trials. 2011; 12: 188
- 13.
Response to: Pre-referral rectal artesunate in severe malaria: a flawed trial.Trials. 2011; 12: 189
- 14.
HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria.Clin Infect Dis. 2009; 49: 336-343
- 15.
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever.Lancet. 1975; 1: 1211-1213
- 16.
Efficacy of bone marrow, blood, stool and duodenal contents cultures for bacteriologic confirmation of typhoid fever in children.Pediatr Infect Dis. 1985; 4: 496-498
- 17.
Bone marrow aspirate culture superior to streptokinase clot culture and 8 ml 1:10 blood-to-broth ratio blood culture for diagnosis of typhoid fever.Am J Trop Med Hyg. 1986; 35: 836-839
- 18.
Relative sensitivity of blood and bone marrow cultures in typhoid fever.Trop Doct. 1991; 21: 174-176
- 19.
Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features.J Clin Microbiol. 2001; 39: 1571-1576
- 20.
Enteric fever: diagnostic value of clinical features.Kathmandu Univ Med J (KUMJ). 2006; 4: 307-315
- 21.
Coinfections and Malaria.in: Kremsner PG Krishna S Encyclopedia of Malaria. Springer, New York, NY2020: 1-10
- 22.
Improving the diagnosis of severe malaria in African children using platelet counts and plasma PfHRP2 concentrations.Sci Transl Med. 2022; 14eabn5040
- 23.
Management of severe malaria.https://apps.who.int/iris/bitstream/handle/10665/79317/9789241548526_engpdf?sequence=1Date: 2012Date accessed: November 30, 2022
- 24.
Use of rectal artesunate for severe malaria at the community level, Zambia.Bull World Health Organ. 2019; 97: 810-817
- 25.
Adherence to the referral advice after introduction of rectal artesunate for pre-referral treatment of severe malaria at the community level: a noninferiority trial in the Democratic Republic of the Congo.Malar J. 2019; 18: 438
- 26.
Compliance with referral advice after treatment with prereferral rectal artesunate: a study in 3 sub-Saharan African countries.Clin Infect Dis. 2016; 63: S283-S289
- 27.
Pre-referral rectal artesunate treatment by community-based treatment providers in Ghana, Guinea-Bissau, Tanzania, and Uganda (Study 18): a cluster-randomized trial.Clin Infect Dis. 2016; 63: S312-S321
- 28.
The preclinical discovery and development of rectal artesunate for the treatment of malaria in young children: a review of the evidence.Expert Opin Drug Discov. 2021; 16: 13-22
- 29.
Community access to rectal artesunate for malaria (CARAMAL): a large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda.PLoS Glob Pub Health. 2022; 2e0000464
- 30.
Strides Shasun's rectal artesunate product receives WHO prequalification.https://www.mmv.org/newsroom/news/strides-shasun-s-rectal-artesunate-product-receives-who-prequalificationDate: June 21, 2018Date accessed: November 30, 2022
- 31.
Cipla launches quality-assured rectal artesunate suppositories for severe malaria in young children.https://www.mmv.org/newsroom/press-releases/cipla-launches-quality-assured-rectal-artesunate-suppositories-severeDate: July 25, 2017Date accessed: November 30, 2022
- 32.
Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children <5 years of age: a multi-country observational study.BMC Med. 2022; 20: 343
- 33.
Health worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate: an operational study in three high burden countries.medRxiv. 2021; (published online Nov 30.) (preprint).
- 34.
Acceptability of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years by health workers and caregivers in the Democratic Republic of the Congo, Nigeria and Uganda.Malar J. 2022; 21: 322
- 35.
Starting at the community: treatment seeking pathways of children with suspected severe malaria in Uganda.medRxiv. 2021; (published online Dec 11.) (preprint).
- 36.
Treatment-seeking for children with suspected severe malaria attending community health workers and primary health centres in Adamawa State, Nigeria.medRxiv. 2021; (published online Dec 5.) (preprint).
- 37.
Danger signs and management of suspected severe malaria cases at community level and in referral health facilities: an operational study in the Democratic Republic of the Congo.Malar J. 2022; 21: 274
- 38.
Real world costs and barriers to the successful implementation of rectal artesunate as pre-referral treatment for severe malaria in sub-Saharan Africa.medRxiv. 2022; (published online May 27.) (preprint).
- 39.
Clonal expansion of artemisinin-resistant Plasmodium falciparum in Uganda is associated with substandard treatment practices.SSRN. 2021; (published online Dec 17.) (preprint).
- 40.
Pre-referral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda.BMJ Glob Health. 2022; 7e008346
- 41.
Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years of age: a multi-country observational study.BMC Med. 2022; 20: 343
- 42.
The use of rectal artesunate as a pre-referral treatment for severe P. falciparum malaria.https://www.who.int/publications/i/item/9789240042513Date: Jan 27, 2022Date accessed: November 30, 2022
- 43.
Stopping prereferral rectal artesunate—a grave error.BMJ Glob Health. 2022; 7e010006
- 44.
Molecular surveillance of drug resistance: Plasmodium falciparum artemisinin resistance single nucleotide polymorphisms in Kelch protein propeller (K13) domain from Southern Pakistan.Malar J. 2021; 20: 176
- 45.
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.Malar J. 2009; 8: 253
- 46.
The de novo selection of drug-resistant malaria parasites.Proc Biol Sci. 2003; 270: 545-554
- 47.
Guidelines for the treatment of malaria. Third edition.https://www.afro.who.int/publications/guidelines-treatment-malaria-third-editionDate: April, 2015Date accessed: November 30, 2022
Article info
Publication history
Published: December 19, 2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.